Implantica included in Nasdaq First North 25 index
Implantica AG (publ) today announced it is joining the FN 25 index from the start of trading this morning.
Implantica’s inclusion in the First North 25 index was announced by Nasdaq in its latest semi-annual review of the index. First North 25 consists of the largest and most traded shares listed on the First North Growth Market.
Implantica CEO Peter Forsell said: “It is an honor to be selected for inclusion in the FN 25 index and validates the high interest we have received from investors since our listing in September. We look forward to an exciting future where eHealth is anticipated to completely reform healthcare, and we believe our advanced eHealth platform will place us in the forefront of this transformation."
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, firstname.lastname@example.org
The information was sent for publication, through the agency of the contact person set out above, on January 4, 2021 at 08:00 a.m. CET.
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.